Daiichi Sankyo Eyes V-Shaped Recovery from Olmesartan Patent Cliff: 5-Year Plan

Daiichi Sankyo President and CEO Joji Nakayama Daiichi Sankyo unveiled its new five-year plan through FY2020 on March 31, predicting a patent cliff for its flagship hypertension drug olmesartan in FY2017 and a “V-shaped recovery” thereafter with the anticoagulant edoxaban...read more